Nintedanib Aurobindo (Nintedanib)

Nintedanib blocks several receptor tyrosine kinases—VEGFR, FGFR, and PDGFR—thereby reducing fibroblast proliferation, extracellular matrix formation, and new blood‑vessel growth. This dual antifibrotic and anti‑angiogenic action limits tissue scarring in the lungs and hampers tumor blood supply.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s condition, weight, renal and hepatic function, and concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of nintedanib in pregnancy and lactation has not been established. It is generally advised to avoid use in pregnant or nursing women unless the potential benefit justifies the potential risk, and this decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and required import documentation.

Nintedanib differs from pirfenidone, the other approved antifibrotic for idiopathic pulmonary fibrosis, by targeting a broader range of tyrosine kinases. This results in a distinct side‑effect profile and may be preferred in patients who cannot tolerate pirfenidone or who have concurrent oncologic indications.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Nintedanib Aurobindo is taken orally, usually with food to reduce gastrointestinal discomfort. The tablets should be swallowed whole with a full glass of water and not crushed or chewed.

The most serious risks include liver injury (elevated transaminases or hepatitis), severe bleeding events, and cardiovascular complications such as hypertension or arterial thrombotic events. Patients should be monitored regularly for these conditions and report any concerning symptoms promptly.

Patients with known hypersensitivity to nintedanib or any of its excipients, those with severe hepatic impairment, uncontrolled bleeding disorders, or who are pregnant without a clear benefit should avoid using the medication. Final eligibility is determined by the treating physician.